title: Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
authors: IRCCS Institute for Pharmacological Research "Mario Negri", Via Camozzi, 3 c/o Villa Camozzi, Ranica, 24020, Bergamo, Italy. lgarattini@marionegri.it.
authors: Livio
authors: L
authors: Garattini
authors: IRCCS Institute for Pharmacological Research "Mario Negri", Via Camozzi, 3 c/o Villa Camozzi, Ranica, 24020, Bergamo, Italy.
authors: Francesca
authors: F
authors: Ghislandi
authors: IRCCS Institute for Pharmacological Research "Mario Negri", Via Camozzi, 3 c/o Villa Camozzi, Ranica, 24020, Bergamo, Italy.|Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
authors: Milene Rangel
authors: MR
authors: Da Costa
mesh_terms: D003362:Cost-Benefit Analysis; D005062:European Union; D000068717:Glatiramer Acetate / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics* / Q000627:therapeutic use; D016899:Interferon-beta / Q000191:economics* / Q000627:therapeutic use; D018803:Models, Economic; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics
chemical_list: D007166:Immunosuppressive Agents; D000068717:Glatiramer Acetate; D016899:Interferon-beta